Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, today announces the initiation of "a partially-blinded ...

"Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis" was originally created and published by ...

New research shows calves fed waste milk develop different immune cell and cytokine profiles than those fed salable milk, ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...

DEM BioPharma, Inc. (DEM Bio), a biopharmaceutical company dedicated to discovering novel targets for solid tumors and ...

Treg therapeutic designed to preferentially traffic towards its ligand CXCL12 over expressed in the bone marrow and spleen in myelofibrosis. -- CK0804 engages with antigen presenting cells within ...

Preliminary but promising.Those three words emerged as a recurring theme in conversations about several abstracts presented at this year’s ASH Annual Meeting and Exposition that examined the effects ...

Researchers used a panel to assess the presence of circulating tumor DNA in plasma samples and detected changes in genes related to the development of adenocarcinoma that indicated both actionability ...

Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease — HONG KONG and SHANGHAI and ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.

A major global study warns cancer cases and deaths will surge by 2050, with low- and middle-income countries facing the fastest rise without urgent action.